Science

Share Community
Report Community
2
US Patent Office Issues Decision to Grant Patent for USMI’s Cold Atmospheric Plasma for the Selective Ablation of Cancer Cells

US Patent Office Issues Decision to Grant Patent for USMI’s Cold Atmospheric Plasma for the Selective Ablation of Cancer Cells

6 years ago
Anonymous $hM_jrxqbr-

https://www.businesswire.com/news/home/20180724005196/en/

TAKOMA PARK, Md.--(BUSINESS WIRE)--Jul 24, 2018--, a U.S. FDA registered life science, biomedical and robotic device company (a subsidiary of US Patent Innovations, LLC), announced today that the United States Patent Office (USPO) has issued USPI patent No. 10,023,858 B2, further expanding its intellectual patent property portfolio for the application of delivering Cold Atmospheric Plasma (CAP) technology to selectively target cancer cells.

Researchers at the Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), Takoma Park, Md., have successfully demonstrated the use of CAP for elevating TRAIL-R1 (Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 1 expression in cancer cells to induce apoptosis.

US Patent Office Issues Decision to Grant Patent for USMI’s Cold Atmospheric Plasma for the Selective Ablation of Cancer Cells

Jul 24, 2018, 3:20pm UTC
$hM_jrxqbr-
https://www.businesswire.com/news/home/20180724005196/en/ > TAKOMA PARK, Md.--(BUSINESS WIRE)--Jul 24, 2018--, a U.S. FDA registered life science, biomedical and robotic device company (a subsidiary of US Patent Innovations, LLC), announced today that the United States Patent Office (USPO) has issued USPI patent No. 10,023,858 B2, further expanding its intellectual patent property portfolio for the application of delivering Cold Atmospheric Plasma (CAP) technology to selectively target cancer cells. > Researchers at the Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), Takoma Park, Md., have successfully demonstrated the use of CAP for elevating TRAIL-R1 (Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 1 expression in cancer cells to induce apoptosis.